Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|January 2, 2019
- Pharmaceutical Technology-01-02-2019
- Volume 43
- Issue 1
Tabletop Spray Dryer
Fluid Air’s portable PolarDry Electrostatic Spray Dryer Model 0.1 is compact in size while retaining the same features of previous spray dryers.
Fluid Air’s portable PolarDry Electrostatic Spray Dryer Model 0.1 is compact in size while retaining the same features of previous spray dryers. The spray dryer’s smaller dimensions allow the system to fit inside spaces such as most lab fume or containment hoods.
The dryer produces small-scale samples with minimum product loss and can be easily disassembled for autoclave sterilization, the company reports. The system is compatible with optional high temperature and ultrasonic spray drying nozzles that ensure efficient microencapsulation. The ultrasonic nozzle is suited for creating small particles less than 10 microns, and formulators still have the choice to use the Model 0.1 as a standard spray dryer with two fluid nozzles. Other features include a programmable logic controller system with data-logging, zero need for an atomizing heat, and low volatility loss.
Articles in this issue
over 7 years ago
Packaging Peril: ‘No-Deal’ Brexit May Lead to Missed Deadlineover 7 years ago
Looking Beyond the Deadlineover 7 years ago
Great Expectationsalmost 8 years ago
Smarter Packaging Comes to the Pharma Marketalmost 8 years ago
Continuous Processing: Challenges and Opportunities of Virus Filtrationalmost 8 years ago
Improved Mixer Lift and Seal Designsalmost 8 years ago
Microplate Spectrophotometeralmost 8 years ago
Electrical Position Indicator for Linear Actuatorsalmost 8 years ago
FDA Marks Record Year for New Drug Approvalsalmost 8 years ago
Internal and External Challenges to Pharma in 2019Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5